Issues in clinical trial design for tumor marker studies.
暂无分享,去创建一个
[1] D. Schaid,et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. , 1999, Journal of the National Cancer Institute.
[2] H. McLeod,et al. Tumour markers of prognosis in colorectal cancer , 1999, British Journal of Cancer.
[3] J. Grem. 5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development , 2000, Investigational New Drugs.
[4] S. Groshen,et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] Daniel F. Hayes,et al. Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? , 2004, Breast Cancer Research and Treatment.
[6] L. Påhlman,et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] P. Johnston,et al. Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] H E Rockette,et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Groshen,et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Johnston,et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.
[11] H. Blomgren,et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] F. Jänicke,et al. Do we need better prognostic factors in node-negative breast cancer? Pro:. , 2000, European journal of cancer.
[13] A. Scharl,et al. Do we need better prognostic factors in nodal-negative breast cancer? Contra. , 2000, European journal of cancer.
[14] D. Grignon,et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. , 1997, Journal of the National Cancer Institute.
[15] D. G. Altman,et al. Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.
[16] Geert Molenberghs,et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.
[17] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[18] D. Sargent,et al. Statistical issues in tumor marker studies. , 2000, Archives of pathology & laboratory medicine.
[19] S. Groshen,et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] Stephen L. George,et al. Sample size requirements and length of study for testing interaction in a 1 × k factorial design when time-to-failure is the outcome , 1993 .
[21] A. Paradiso,et al. Colorectal Clinical Experimental Oncology Laboratory and 2 , 2022 .
[22] I. Henderson,et al. The relationship between prognostic and predictive factors in the management of breast cancer , 2004, Breast Cancer Research and Treatment.
[23] G. Clark. Prognostic and predictive factors for breast cancer , 1995, Breast cancer.
[24] P J Catalano,et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. , 2001, The New England journal of medicine.
[25] A. deMoura,et al. [Cancer of the prostate]. , 1962, Jornal do medico.
[26] S L George,et al. Reducing patient eligibility criteria in cancer clinical trials. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Kerr,et al. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial , 2000, The Lancet.
[28] P. Johnston,et al. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. , 1991, Cancer research.
[29] S. Barni,et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] D. Rubin,et al. Statistical Analysis with Missing Data. , 1989 .
[31] D. Hayes,et al. Do we need better prognostic factors in node-negative breast cancer? Pro, Contra and arbiter , 2000 .
[32] A. Paradiso,et al. Predictive role of thymidylate synthase (TS) and p53 primary tumor expression in advanced colorectal cancer , 1997 .